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The increasing incidence of obesity and the metabolic syndrome is disturbing. The activation of inﬂammatory pathways, used
normally as host defence response, reminds us of the seriousness of this condition. There is most probably more than one
cause for the activation of inﬂammation, a timeline of events related to the deterioration of metabolic homeostasis presenting
along variable routes. Apparently, metabolic overload evokes several stress reactions, such as oxidative, inﬂammatory, organelle,
and cell hypertrophy stresses, generating vicious cycles that amplify each other leading to dysfunction. Adipocyte hypertrophy,
through purely physical reasons, facilitates cell rupture, what will evoke an inﬂammatory reaction. Inability of adipose tissue
development to engulf all incoming fat leads to fat deposition in other organs, mainly in the liver, with marked consequences
on insulin resistance. The oxidative stress which accompanies feeding, particularly when there is an excessive ingestion of
fat and/or other macronutrients without concomitant ingestion of antioxidant-rich foods/beverages, may contribute to the
inﬂammatory markers attributed to obesity. Moreover, recent data on the microbiota and its interaction with food and with
obesity brought new hypothetic mechanisms for the obesity/fat diet relationship with inﬂammation. Beyond these common
confounders, other phenomena, for instance, psychological and/or circadian rhythm disturbances, may likewise contribute to the
raise of oxidative/inﬂammatory status. The diﬃculty in the management of the obesity/metabolic syndrome pathologies is linked
to their multifactorial nature where environmental, genetic, and psychosocial factors interact through highly complex networks.
1.Obesityandthe Metabolic Syndrome
The incidence of the metabolic syndrome is high and
increasing. Metabolic syndrome refers to a constellation of
disturbances including glucose intolerance, central obesity,
dyslipidemia (hypertriglyceridemia, elevated nonesteriﬁed
fatty acids (NEFAs), and decreased high-density lipoprotein
(HDL) cholesterol), and hypertension [1]. It can present in
several forms, according to the combination of the diﬀerent
components of the syndrome, and it is well established that
it increases the risk for the development of cardiovascular
disease, type 2 diabetes, and cancer [2–4]. However, it
is not yet clariﬁed how it begins and how the diﬀerent
components are causally connected among them. Diﬀerent
study groups have drawn special attention to one or another
component. For example, the American Association of
Endocrinology does not consider obesity as a component
and highlights the importance of insulin resistance to
the syndrome [5]. As a matter of fact, obesity and the
metabolic syndrome do not completely overlap, evidence
being now clear as to the existence of “benign” obesity [6–
10]. In this metabolically healthy obese phenotype plasma
concentrations of adiponectin are high, in good agreement
with the eﬀect of adiponectin overexpression in ob/ob mice
that results in expansion of fat mass and protection against
metabolic comorbidities [7]. The initial deﬁnition of the
World Health Organization considered insulin resistance
a key feature of the metabolic syndrome [11, 12], while
the more recent National Cholesterol Education Program
(NECP):Adult Treatment Panel III (ATP III) deﬁnition adds
equal weight to any of the components of the syndrome:
glucose intolerance, obesity, hypertension, and dyslipidemia
[13].
Welsh et al. investigated the causal direction of the
relationship between adiposity and inﬂammation using a
bidirectional Mendelian randomization approach and came2 Mediators of Inﬂammation
to the conclusion that greater adiposity conferred by fat mass
and obesity-associated gene and melanocortin receptor 4
single nucleotide polymorphisms led to higher C-reactive
protein (CRP) levels, with no evidence for any reverse
pathway [14]. Although this interesting ﬁnding needs to be
conﬁrmed and extended to other inﬂammatory markers, it
supports the emphasis we are giving to adipose tissue in
metabolic syndrome-associated chronic inﬂammation [15].
Whateveritsorigin,beitornotobesitythemaininitiator,the
chroniclow-gradeinﬂammatoryconditionthataccompanies
the metabolic syndrome has been implicated as a major
player in both the installation of the syndrome and its
associated pathophysiological consequences [16]. In good
agreement with this interpretation of things, weight loss of
obese patients is repeatedly veriﬁed to be associated with a
decrease of inﬂammation biomarkers [17–21] accompanied
by improvement of metabolic parameters, namely, insulin
sensitivity [22–26].
2. The Inﬂammatory Response
Inﬂammation is a physiological response of the organism to
harmful stimuli, be they physical, chemical, or biological.
The response provided usually conducts to the reestablish-
ment of homeostasis. It involves the coordinated action of
many cell types and mediators, whose intervention depends
on the nature of the initial stimulus and ensuing responses
thereafter. The normal acute inﬂammatory response involves
the delivery of plasma components and leucocytes to the
site of insult and is initiated by tissue-resident macrophages
and mast cells leading to a production of diﬀerent types of
inﬂammatory mediators (chemokines, cytokines, vasoactive
amines, eicosanoids, and products of proteolytic cascades)
[16]. The activated endothelium allows extravasation of
neutrophils and soluble components to the tissue, where
they become activated releasing toxic agents and proteolytic
enzymes to the extracellular milieu [27]. If successful, the
injurious agent is eliminated and inﬂammation resolution
and tissue repair follow. This is achieved by switching the
lipid mediators from proinﬂammatory (e.g., prostaglandins)
to anti-inﬂammatory and pro-resolution ones (lipoxins,
resolvins, and protectins) and by the action of tissue-
resident and newly recruited macrophages [27]. Tissue
leucocytes undergo apoptosis and are phagocytised by the
macrophages that leave the inﬂamed site by lymphatic
drainage [28]. The apoptosis of inﬂammatory cells is a
nonphlogistic physiological process of removing dead cells
and is essential for the resolution of inﬂammation [16]w i t h
theaddedadvantagethatafterengulﬁngtheseapoptoticcells,
macrophages acquire a phenotype conductive to resolution,
releasing anti-inﬂammatory signals such as interleukin-(IL-)
10 and transforming growth factor β (TGFβ)[ 29]. However,
if the neutralization and removal of the noxious stimuli or
eveniftheclearanceofapoptoticinﬂammatorycellsfromthe
inﬂamed tissue fail, the inﬂammatory process persists and
a state of chronic inﬂammation or autoimmunity may arise
with diﬀerent agents being recruited, namely, T lymphocytes
and the development of lymphoid inﬁltrates in the tissue
[30]. It has recently been demonstrated that the chronic
inﬂammatory condition associated with morbid obesity
is characterized by a continuous activation of the innate
immune system [31].
3. Inﬂammation inObesityand
the MetabolicSyndrome
The inﬂammatory state that accompanies the metabolic
syndrome shows a quite peculiar presentation, as it is not
accompanied by infection or sign of autoimmunity and no
massivetissueinjuryseemstohavetakenplace.Furthermore,
the dimension of the inﬂammatory activation is not large
and so it is often called “low-grade” chronic inﬂammation.
Otherresearchershaveattempted tonamethis inﬂammatory
state as “metaﬂammation”, meaning metabolically triggered
inﬂammation [32], or “parainﬂammation” as a term to
deﬁne an intermediate state between basal and inﬂammatory
states [33]. Whatever the term used, the inﬂammatory
process that characterizes the metabolic syndrome seems to
have its own unique features, its mechanisms being far from
fully understood [15].
Recent studies have been conﬁrming the positive asso-
ciation between obesity indices and inﬂammatory markers,
m a i n l yC R Pp r o t e i ni nw o m e n[ 34, 35], but also other
inﬂammatory markers, both in women and men [31, 36].
Increasing incidence of the metabolic syndrome all over
the world accompanies adoption of the so-called modern
Western lifestyle [37, 38]. The main negative features of this
lifestyle include stress (long-term and continuous, psycho-
logical), positive energy balance (excessive energy intake and
low physical activity), low-quality food (both high fat and
energy dense, and at the same time poor in micronutrients),
and disruption of chronobiology. An acute disturbance in
any of the physiological regulatory systems evokes reactions
that tend to reestablish equilibrium. When the stimuli, even
of moderate magnitude, tend to be repetitive or chronic,
change and allostasis in one system impact on the other, and
vicious cycles are created and reinforced [1].
A state of positive energetic balance, with fat accrual
along time, demands plasticity of the adipose tissue, which
includes formation of new adipocytes and also physical
compliance of the anatomical spaces for adipose tissue
expansion [39]. Otherwise two deleterious phenomena
ensue, hypertrophic growth of adipocytes that will rupture
more and more frequently and fat deposition in organs
other than adipose tissue [40], mainly in the liver, with
local (nonalcoholic fatty liver disease) and systemic (insulin
resistance) consequences. It is well known that the lack of
adipose tissue, as evident in lipodystrophy [41], may equally
lead to the development of metabolic syndrome.
After a meal, fatty acids are taken up by adipocytes,
and during fasting or increased expenditure periods, the
fatty acids are released to the blood stream. This is usually
achieved through the coordinated action of hormones,
catecholamines and insulin being the chief regulators of this
balance[42].Notonlyistheadipocytemetabolismalteredby
thesehormones,butthesehormonesalsoregulatebloodﬂow
into the adipose tissue through the regulation of vascular
tone, such that there is increased blood supply when theMediators of Inﬂammation 3
organ is metabolically active [43]. Inadequate blood supply
in a growing adipose tissue results in reduced oxygenation
that may also contribute to inﬂammation [44].
The homeostatic capacity of adipose tissue development,
with adipocyte hyperplasia responding to fat accommoda-
tion needs, has its limits and may contribute, in people that
are not able to develop benign obesity, to adipocyte hyper-
trophy and the inﬂammatory response. Obesity researchers
aimed, for some time, to ﬁnd and study antiadipogenic
agents to combat/prevent obesity, but that concept is no
longer defensible [45–48].
3.1. Adipocyte Dysfunction and Inﬂammation. An increase in
circulating concentration of NEFA [42] reﬂects the inability
of the adipose tissue to buﬀer the excess nutrient intake
and is related to the dyslipidemic state that is typical of the
metabolic syndrome. When overload becomes present, the
liver increases the production of apo-B containing particles
that carry triacylglycerols to the adipose tissue resulting in
low-density lipoprotein (LDL) formation [49]. This occurs
in visceral adipose tissue very eﬃciently and this depot is
also more capable of releasing lipids in times of requirement.
The subcutaneous adipose tissue has usually a much larger
capacity to store lipids given its usually larger size. This
may explain why subcutaneous adipose tissue appears to be
protective in terms of metabolic syndrome and why men,
who for genetic and hormonal reasons possess a smaller
subcutaneous adipose tissue compartment, achieve earlier
the limit of that depot and overuse the visceral depot.
When the capacity of both locations is overwhelmed, the
conversionofverylow-densitylipoprotein(VLDL)orsimilar
particles is delayed and hypertriglyceridemia originates [42].
Furthermore, other tissues are used for lipid accumulation
(e.g., liver, muscle, pancreas, and heart) [40]. As these organs
are not able to store lipids without harm to their functions,
lipotoxicity may be the result culminating, in the case of
muscle, liver, and pancreas, in insulin resistance.
Although it has become evident that adipocytes are
involved in innate immunity, only recently was the presence
of toll-like receptors (TLRs) in these cells described. The two
most widely studied TLRs are TLR2 and TLR4, which are
activated by bacterial lipoproteins and by lipopolysaccharide
(LPS), respectively [50]. The engagement of either receptor
leads to translocation of nuclear factor κB( N F κB) to
the nucleus. In addition to their early recognized role in
immunity, a participation in the regulation of metabolism
is also being attributed to TLRs [50]. It has been shown that
these receptors may be activated by speciﬁc types of lipids. It
had already been demonstrated that the fatty acid moiety of
TLRligandswasessentialfortheiractivation[51]andthisled
totheinvestigationofitspossibleactivationbydiﬀerentsorts
of lipids. Thus, it was discovered that saturated fatty acids
activate both TLR2 and TLR4 and, instead, unsaturated fatty
acids inhibit TLR-mediated signalling and gene expression
[16]. This was also demonstrated with diet-derived saturated
fattyacids,whichincreasedTLR-mediatedexpressionofIL-6
and tumor necrosis factor α (TNF-α), whereas unsaturated
fatty acids had no eﬀect alone but inhibited the saturated
fatty acid-induced increase in TNF-α expression [16]. TLR4
has been found in murine preadipocytes 3T3-L1 and both
TLR2 and TLR4 have been shown to be present and func-
tional in human subcutaneous adipocytes [16]. Activation
of TLRs results in synthesis of proinﬂammatory factors
such as TNF-α, IL-6, and chemokines [16]. Considering the
implication of the increase in circulatory NEFA in adipose
tissue dysfunction, it is very likely that the activation of TLRs
takes place in hyperlipidemic states, resulting in ampliﬁed
inﬂammation and contributing to the development or
aggravation of the metabolic syndrome [50].
There is compelling evidence showing that exposure of
adipocytes to several types of stressors (oxidative stress,
inﬂammatory cytokines, and elevated concentrations of
fatty acids) induces cellular responses mediated by cel-
lular kinases, including mitogen-activated protein kinases
(MAPK; p38MAPK, c-Jun N-terminal kinase (JNK) and
extracellular signal-regulated kinase), inhibitor of NFκB
kinase (IKK) β, mammalian target of rapamycin (mTOR),
and various conventional and atypical protein kinases C
(PKC). Some of these kinases involved in stress-sensing
are related to the impairment of insulin action through
the stimulation of insulin receptor substrate (IRS) serine
phosphorylation but also often activate targets related to the
inﬂammatory response [32]. The three main kinases that
havebeenrelatedtothisinactivationofIRSareJNK,IKKand
PKC [16]. They exert powerful eﬀects on proinﬂammatory
gene expression, through activation of activator protein-1
(AP-1) complexes and NFκB[ 52].
Metabolic dysfunction due to metabolic overload also
seems to be mediated through IKKβ.T h er e d u c t i o no fI K K β
expression partly protects mice from obesity-induced insulin
resistance, and the inhibition of this kinase achieved by high
doses of salicylates has been shown to improve insulin sensi-
tivity in humans and other experimental models [16]. PKC
has also been shown to constitute an important interface
between metabolic deregulation, inﬂammation, and insulin
resistance. This kinase (isoform θ in skeletal muscle and
δ in the liver) can be activated by fatty acid metabolites
that accumulate due to metabolic pathway burden such as
fattyacylCoAanddiacylglycerol,leadingtoinhibitory serine
phosphorylation of IRS and attenuation of insulin signalling
[16]. Furthermore, PKCθ is known to activate IKK and
might contribute to insulin resistance and ampliﬁcation of
inﬂammation.
The metabolic stress to which adipose tissue is subjected
in obesity, together with other already mentioned stresses,
resultsinorganelledysfunction,particularlyinmitochondria
and the endoplasmic reticulum (ER). The ER is a cytosolic
organelle that participates in the regulation of lipid, glucose,
cholesterol, and protein metabolism, apart from being
the site of triacylglycerol droplet formation. In the obese,
the adipocyte may be especially challenged, given that it
is required to secrete large amounts of substances and
synthesise lipids. Under such conditions, ER function may
be impaired leading to the accumulation of misfolded or
unfolded proteins in its lumen. As a way to cope with it, the
stressedendoplasmicreticulumengagestheunfoldedprotein
response (UPR). The UPR functions via signalling through
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found in the ER membrane: PKR-like eukaryotic initia-
tion factor 2a kinase (PERK), inositol-requiring enzyme-1
(IRE-1), and activating transcription factor-6 (ATF-6) [53].
Their activation attenuates the cellular workload (decreasing
protein translation, clearance, and degradation of excess
proteins from the ER lumen) and induces repair (induction
of an antioxidant response and of chaperone transcription
to assist with the unfolded proteins) and ER biogenesis,
towards recovery and survival of the cell. However, if the
ER stress is not relieved, the UPR may also induce cell
death via apoptosis. JNK, after activation by IRE-1, is an
important eﬀector in this action and, apart from this role, it
may lead to a variety of other downstream eﬀects depending
on the cellular context, such as cell survival, inﬂammation,
and insulin resistance. The activation of inﬂammation by
the UPR also depends upon the IKK-NFκBp a t h w a y ,a l s o
through IRE-1α, resulting in increased TNF-α and IL-6
production, further supporting its contribution to insulin
resistance [16].
Obesity is associated with deregulated lipid and car-
bohydrate metabolism. An increase in either one of these
substrateswillalsoincreasethedemandonthemitochondria
and the utilization of the electron transport chain [54]. As
inmetabolicallyactivetissuesundergoingincreaseddemand,
there is usually relative hypoxia, together with the increased
need for nutrient oxidation. This generates unusual amounts
of reactive oxygen species. Oxidative stress activates kinases
like JNK, p38 MAPK, and IKK that may directly interfere
with insulin signalling or indirectly via induction of NFκB
and increased cytokine production [16].
Furthermore, the enhanced ﬂux through alternative
metabolic pathways leads to the generation of other metabo-
lites that may themselves be related to impairment of insulin
function and inﬂammation. Examples include fatty acyl
CoA, diacylglycerol, which activate PKC serine kinases, and
ceramide, which can undergo phosphorylation to ceramide-
1-phosphate and promote inﬂammation or originate sec-
ondary metabolites with the same eﬀect. Ceramide may also
activate protein phosphatase 2A, which inactivates PKB/Akt
and attenuates insulin response, contributing to insulin
resistance [55].
3.2. Visceral Obesity. Adipose tissue pathogenicity diﬀers
according to adipose tissue localization, visceral, or sub-
cutaneous [56]. Visceral adiposity seems to be an inde-
pendent predictor of insulin sensitivity [57–59], impaired
glucose tolerance [60], elevated blood pressure [61, 62], and
dyslipidemia [58, 63]. Visceral fat is a highly active tissue
from the metabolic point of view. It is apparently more
susceptibletolipolysisthansubcutaneousadiposetissue[64]
and is associated with higher production of TNF-α [64, 65],
plasminogen activator inhibitor-1 (PAI-1) [66], IL-6, and
CRP [67]. On the other hand, it is a feabler producer of
adiponectin, an adipokine more strongly correlated with
subcutaneous fat [68]. Bahceci and collaborators [69]f o u n d
a positive correlation between adipocyte size and TNF-α,I L -
6, and high-sensitivity CRP. On the other hand, adiponectin
was found to be negatively correlated with adipocyte size.
Although visceral obesity seems to play a central role in
the metabolic syndrome, being generally considered much
more proinﬂammatory [70], not all patients with the syn-
dromepresent thisfeature.Perhapsmoreimportant thanthe
amountofaccumulatedfatintheabdominalcavityisthesize
of abdominal adipocytes. We have shown that big adipocytes
a r em o r ep r o n et or u p t u r e[ 45], and cell rupture will
obviously constitute a focus of inﬂammation. Macrophage
crowns surrounding dead adipocytes in adipose tissue, as
shown by Cinti and collaborators [71], are compatible with
this hypothesis.
Asalreadystated,adipocytesbehaveasimmunecells[72–
75] and are able to synthesize and release a huge amount of
proinﬂammatory adipokines and cytokines including leptin,
resistin, PAI-1, IL-6, TNFα, retinol-binding protein 4 (see
[16]), IL-1β, monocyte chemoattractant protein-1 (MCP-
1), CRP, macrophage migration inhibitory factor (MIF) (see
[76]), chemokines from the CC and CXC families [77], and
more recently described cytokines such as IL-18 [78]a n d
IL-33 [79], most of which, if not all, are involved in insulin
resistance [76, 80]. But beyond the capacity of adipocytes to
secrete these and possibly more proinﬂammatory cytokines,
under circumstances of obesity and/or nutrient overload,
adipose tissue macrophages do also provide their coun-
terpart of insulin-resistance inducing cytokines. Moreover,
obese adipose tissue do also contain lymphocytes that
participate in and reinforce the inﬂammatory reaction and
consequent insulin resistance [77, 81, 82].
Whereas subcutaneous adipocytes can also become
hypertrophic, and most probably do also rupture, visceral
adipocytes, besides being supported by much less dense
connective tissue in comparison with subcutaneous adipose
tissue, are frequently subject to sudden pressure variations
associated with cough, physical exercises [83], and sleep
apnea [84, 85]. Intra-abdominal pressure is higher in
obese patients [86], what may also impact on adipocyte
stability. Preadipocytes of upper-body obese women exhibit
reduced diﬀerentiation and are more prone to apoptosis
than preadipocytes isolated from adipose tissue of lower-
body obese or lean women [87]. The factors involved
in this preadipocyte behaviour deserve investigation [88].
Moreover, it has been proposed that visceral adipose tissue
growthismainlyduetohypertrophy,whileinotherlocations
there may be mainly growth through hyperplasia [89]. The
physical constrains presented inside the abdominal cavity
may halt adipogenic diﬀerentiation of adipose tissue precur-
sors reducing the number of competent cells to accumulate
excessive energy ingested. As a matter of fact, it has been
shown that stretching inhibits adipocyte diﬀerentiation [16].
In an interesting model of diet-induced metabolic syn-
drome, the fructose-fed rat, the animals exhibit a series of
metabolic syndrome features but do not weigh more than
controls. However, their abdominal adipocytes are hyper-
trophic, a modiﬁcation prevented by blockade of the renin-
angiotensin system [90]. Functional relationships between
adipocytes and the renin-angiotensin-aldosterone system
[91] or between adipocytes and adrenocortex/aldosterone
[92] do probably deserve more attention. A critical role for
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in determining adipocyte responses implicated in obesity-
associated inﬂammation and cardiovascular complications
has recently been demonstrated [93].
Another characteristic of abdominal adipose tissue is
its high metabolic activity and dense vascularisation. This
high vascularisation is most probably due to the action
of angiogenic/proinﬂammatory factors, of which leptin
constitutesanexample[94,95].Ontheotherhand,increased
intra-abdominal pressure, as well as pressure variations, may
easily create periods/zones of hypoxia, contributing to the
productionofhypoxiainduciblefactors.Vascularendothelial
growth factor (VEGF), leptin, adenosine, and substance P,
among others, will impact on other features of the metabolic
syndrome. Furthermore, hypoxia by itself inactivates the
adiponectin promoter [96].
3.3. Diet, Microbiota, and Inﬂammation. Among the com-
plex interaction between genetic, metabolic, and environ-
mental factors that is most probably associated with the
present prevalence of obesity and metabolic syndrome,
dietary patterns are considered of central importance. In
these, attention has been focused over calories, amounts,
and proportions of macronutrients, and their eﬀects on
the energetic balance by themselves, and through metabolic
regulators. Only recently have the acute eﬀects of food
ingestion, taking into consideration the type of food, and the
speciﬁc eﬀects of some nutrients, namely, fatty acids, began
to be studied in relation with obesity and inﬂammation.
Total dietary fat and saturated fat are associated with
insulin resistance and high blood pressure as well as obesity-
related inﬂammation [97]. An immediate postprandial
increase in plasma inﬂammatory markers after a high-fat
meal had been shown in abdominally obese men [98].
Consumption of a saturated fatty acid-rich diet resulted in
a proinﬂammatory “obesity-linked” gene expression proﬁle,
whereas consumption of a monounsaturated fatty acid-rich
dietcausedamoreanti-inﬂammatoryproﬁle[99].Moreover,
acute dietary n-3 PUFA dietary supplementation has been
shown to improve fasting as well as postprandial lipid
metabolism and components of the associated inﬂammatory
response in the JCR:LA-cp rat [100]. Increased central
and overall adiposity in children is associated with higher
circulating adipocyte protein 2 (aP2) concentrations, high
dietary intakes of total fat and saturated fat inﬂuencing aP2
association with insulin resistance and inﬂammation [101].
Intakesoftotalfatandantioxidantvitaminshavebeenshown
to be determinants of subclinical inﬂammation in the same
children [102].
It must, however, be taken into account that inﬂamma-
tory markers increase even after a mixed meal, more so in
children with central obesity [103]. The proinﬂammatory
eﬀect of a high-fat diet per se is shown in a most interesting
investigation by the group of Rankin: people put under a
weight loss diet and that eﬀectively lost weight increased the
concentration of an inﬂammation marker when the diet was
high-fat, diﬀerently from a low-fat high carbohydrate diet
where the inﬂammatory marker decreased with the loss of
weight. They also showed that the proinﬂammatory eﬀect of
the high-fat diet was not dependent on oxidative stress [104,
105]. These results are corroborated in a recently published
experimental research work in mice, where it has been
shown that a shift from a high-fat to a high-carbohydrate
diet improved levels of adipokines and proinﬂammatory
cytokines [106].
Intestinal microbiota, microorganisms which are known
to contribute to digestion and metabolism, have barely
been taken into consideration in this discussion, but for
some recent papers [107–111]. However, the extension and
metabolic gene repertoire of our microbiota are compatible
withhugemetabolicconsequencesforthehostdependingon
the microbiota constitution.
Comparison of microbiota from obese and nonobese
subjects has shown diﬀerent proportions of certain species
[112], but it remains unknown what is cause and conse-
quence, or the metabolic consequences, for the host, of har-
boring diﬀerent microbiota. This remains an almost virgin
soil, in spite of the putative importance of conditioning
the evolution of the microbiota in the metabolic interest of
the host. Some associations between dietary patterns and
resistance to obesity, namely, the importance of the diet
acid load [113], nondigestible plant material [114], or the
richness in certain minerals [115] may indeed include eﬀects
of those elements on the microbiota.
Cani and collaborators have demonstrated that high-
fat feeding increases intestinal permeability and the plasma
concentration of LPS, that is, metabolic endotoxemia, and
that changes in gut microbiota control this metabolic endo-
toxemia and inﬂammation [116]. Therefore, high-fat feed-
ing may have direct proinﬂammatory /anti-inﬂammatory
eﬀects, depending on the nature of fatty acids, long-term
inﬂammatory consequences related with overload of adipose
tissue, and indirectly modulate metabolic endotoxemia and
inﬂammation through eﬀects on the microbiota.
4. Conclusion
It has become evident that the inﬂammatory condition
that is associated with obesity and overweight plays an
important part in the aetiology of the metabolic syndrome
and largely contributes to the related pathological outcomes.
From the reasons here presented, it seems likely that
adipocyte dysfunction lies at the bottom of this question, its
homeostatic functions being overwhelmed due to metabolic
overload. From then on, several vicious cycles exacerbate
the disturbances and lead to an inﬂammatory response,
most intense when adipocytes reach large dimensions and
easily rupture for mechanical reasons. In parallel with
this, the eﬀects of high-fat diets, frequently consumed by
obese subjects, add to the inﬂammatory ﬁre, both directly,
when the fat is rich in saturated fatty acids, and indirectly,
througheﬀectsonthemicrobiotaandintestinalpermeability
(Figure 1).
Progress in the knowledge of this highly complex net-
work of pathophysiological events that include multiple
cell types, cytokines, nutrients, in a variable nervous and
hormonal status, as well as speciﬁc physical constraints
and microbial colonization, will open the way for eﬀec-
tive therapeutic interventions. Inﬂammatory mediators are6 Mediators of Inﬂammation
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Figure 1: Overview of the complex interplay between obesity-inﬂammation-metabolic syndrome: metabolic overload impacts on adipose
tissue, leading to organelle stress with production of ROS and adipokines, as well as activation of kinases that potentiate the transcription
of inﬂammatory genes and interfere with insulin signaling. Hyperthrophy facilitates rupture of adipocytes which attract and activate
macrophagesthatmarkedlyreinforcetheinﬂammatoryprocessthroughfurtherproductionofROSandinﬂammatorycytokines.Production
of adiponectin, an anti-inﬂammatory cytokine, is reduced. Increase of FFA concentration, namely, SFA, coming both from feeding and
adipose tissue overﬂow, accumulates in the liver, among other organs. Fat accumulation in the liver leads to overproduction of LDLs and,
together with IL-6, of CRP. NAFLD is a frequent consequence of these metabolic dysregulations, and all this impacts on insulin sensitivity.
SFAactivatesTOLL-likereceptorsinadipocytes,contributingtotheactivationoftheinﬂammatoryresponse.Fathasalsoeﬀectsonintestinal
permeabilityandonthemicrobiota,withsystemicinﬂammatoryconsequences.Mostexcessmetabolitesandcytokinesproducedthroughout
these processes converge on insulin resistance, a central characteristic of the metabolic syndrome. AP-1: activator protein-1; CRP: C-reactive
protein; FFA: free (nonesteriﬁed) fatty acids; IL-n: interleukins; IKK: inhibitor of NF-κB kinase; IL-6: interleukin-6; Int: intestine; IR: insulin
resistance; JNK: c-Jun N-terminal kinase; LDL: low density lipoprotein; M: microbiota; NAFLD: nonalcoholic fatty liver disease; NF-κB:
nuclear factorκB;OxS: oxidative stress;ROS:reactive oxygen species; PKC:proteinkinase C;SFA:saturatedfattyacids; TAG:triacylglycerols;
TLR: TOLL-like receptors; TNFalpha: tumour necrosis factor alpha.
already showing their usefulness as biomarkers of the
metabolic/inﬂammatory/disease-prone status of patients
with the metabolic syndrome.
But diet will remain playing a crucial role in multiple
aspects of this large picture. And, although much remains to
be known in what respects nutrition, the biggest challenge
will be to reinstall a nonobesogenic lifestyle.
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MCP-1: Monocyte chemoattractant protein-1
MIF: Migration inhibitory factor
mTOR: Mammalian target of rapamycin
NECP: National cholesterol education program
NEFA: Nonesteriﬁed fatty acids
NFκB: Nuclear factor κB
PAI-1: Plasminogen activator inhibitor-1
PERK: PKR-like eukaryotic initiation factor 2a
kinase
PKB: Protein kinase BMediators of Inﬂammation 7
PKC: Protein kinase C
TGFβ: Transforming growth factor β
TLR: Toll-like receptor
TNF: Tumor necrosis factor
UPR: Unfolded protein response
VEGF: Vascular endothelial growth factor
VLDL: Very low-density lipoprotein.
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